[Note: The full text of this article is available free in PDF format at http://www.cadth.ca/media/pdf/E0057_Milnacipran%20for%20Fibromyalgia_cetap_e.pdf ]
1. Milnacipran is an antidepressant that is under investigation for the treatment of Fibromyalgia (a chronic pain disorder).
2. Preliminary evidence suggests that milnacipran may benefit some patients with Fibromyalgia, but adverse effects may limit its use.
3. Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for Fibromyalgia.
Source: Issues in Emerging Health Technologies, Feb 2008, issue # 114:1-4. PMID: 18354855, by Dempsey J.